Regarding the role of m6A methylation in leukemogenesis, it has been suggested that targeting m6A regulators may have therapeutic potential and could be considered for the treatment of DDX41-mutated MDS [30, 40, 41]. This evidence concerns the gene DDX41 and myelodysplastic syndrome.